US Judge Dismisses Shareholder Lawsuit Against Abbott Over Formula Recall

Key Facts

In a move that strengthens the legal standing of major healthcare firms, a federal judge in Chicago has dismissed a shareholder lawsuit accusing Abbott Laboratories of fraud. The case centered on allegations that the company misled investors regarding safety issues at its Michigan plant which led to a massive infant formula recall in 2022. The judge ruled that the plaintiffs failed to provide sufficient evidence or adequately present claims to support allegations of fraud against the company or its executives.

This dismissal reduces significant legal uncertainty and potential financial penalties that have loomed over the mega-cap stock since the recall crisis began. According to market data, Abbott (ABT) shares stood at $100.57 at close on July 22, 2026, having traded within a range of $99.84 to $101.04 during that session. The ruling is viewed as a bullish catalyst for investor sentiment as it closes a major chapter of litigation risk.

Looking ahead, ABT shares remain positioned above the recent low of $99.84 established on July 22, 2026. While the legal victory provides a clear internal catalyst, broader market sentiment may be influenced by upcoming global trade data, including Japan's Balance of Trade figures scheduled for release on July 21, 2026, which often impacts multinational consumer health corporations.